Oxford Biomedica (LON:OXB) Reaches New 52-Week High – Still a Buy?

Oxford Biomedica plc (LON:OXB)’s share price reached a new 52-week high during trading on Wednesday . The company traded as high as GBX 791 and last traded at GBX 789, with a volume of 253045 shares. The stock had previously closed at GBX 739.

Wall Street Analyst Weigh In

A number of analysts have recently weighed in on the company. Deutsche Bank Aktiengesellschaft upped their target price on Oxford Biomedica from GBX 735 to GBX 800 and gave the company a “buy” rating in a research report on Friday, January 9th. Canaccord Genuity Group reissued a “buy” rating and issued a GBX 451 target price on shares of Oxford Biomedica in a report on Tuesday, October 7th. Four analysts have rated the stock with a Buy rating and one has assigned a Hold rating to the stock. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average price target of GBX 606.40.

Oxford Biomedica Trading Down 1.5%

The company has a market capitalization of £1.09 billion, a price-to-earnings ratio of -24.82 and a beta of 1.09. The company has a current ratio of 2.35, a quick ratio of 1.67 and a debt-to-equity ratio of 166.48. The business’s 50 day moving average price is GBX 643.28 and its two-hundred day moving average price is GBX 564.49.

Insider Buying and Selling at Oxford Biomedica

In related news, insider Heather Preston bought 6,175 shares of the firm’s stock in a transaction on Monday, October 20th. The shares were purchased at an average price of GBX 593 per share, with a total value of £36,617.75. Insiders own 34.83% of the company’s stock.

About Oxford Biomedica

Oxford Biomedica (LSE: OXB) is a quality and innovation-led cell and gene therapy CDMO with a mission to enable its clients to deliver life changing therapies to patients around the world.

One of the original pioneers in cell and gene therapy, the Company has more than 25 years of experience in viral vectors; the driving force behind the majority of gene therapies. The Company collaborates with some of the world’s most innovative pharmaceutical and biotechnology companies, providing viral vector development and manufacturing expertise in lentivirus, adeno-associated virus (AAV) and adenoviral vectors.